CIK 0001682852
- Large accelerated filer
Moderna, Inc.
Sign in to watch- Ticker
- MRNA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813467528
- Phone
- +1 617-714-6500
- Business address
- 325 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- Moderna Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $50,775,837
- in 5 filings, $50.8M under 10b5-1 plans
Net −$50,775,837. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-01 | Hoge Stephen President | Sale | −1,072 | $138.03 | $148K | 1,629,031 |
| 2023-02-28 | Klinger Shannon Thyme Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +20,040 | 20,040 | ||
| 2023-02-28 | Klinger Shannon Thyme Chief Legal Officer | Grant or award · Restricted Stock Units | +5,260 | 5,260 | ||
| 2023-02-28 | Hoge Stephen President | Exercise or conversion | +2,410 | 1,630,103 | ||
| 2023-02-28 | Hoge Stephen President | Exercise or conversion · Restricted Stock Units | −2,410 | 9,643 | ||
| 2023-02-28 | Hoge Stephen President | Grant or award · Stock Option (Right to Buy) | +37,217 | 37,217 | ||
| 2023-02-28 | Hoge Stephen President | Grant or award · Restricted Stock Units | +9,768 | 9,768 | ||
| 2023-02-28 | Mock James M Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +20,040 | 20,040 | ||
| 2023-02-28 | Mock James M Chief Financial Officer | Grant or award · Restricted Stock Units | +5,260 | 5,260 | ||
| 2023-02-28 | Garay Arpa Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +20,040 | 20,040 | ||
| 2023-02-28 | Garay Arpa Chief Commercial Officer | Grant or award · Restricted Stock Units | +5,260 | 5,260 | ||
| 2023-02-28 | Bancel Stephane Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +128,830 | 128,830 | ||
| 2023-02-23 | Bancel Stephane Chief Executive Officer | Exercise or conversion | +40,000 | $0.99 | $40K | 5,451,946 |
| 2023-02-23 | Bancel Stephane Chief Executive Officer | Sale | −7,314 | $144.45 | $1.1M | 5,444,632 |
| 2023-02-23 | Bancel Stephane Chief Executive Officer | Sale | −7,486 | $145.25 | $1.1M | 5,437,146 |
| 2023-02-23 | Bancel Stephane Chief Executive Officer | Sale | −12,890 | $146.75 | $1.9M | 5,424,256 |
| 2023-02-23 | Bancel Stephane Chief Executive Officer | Sale | −8,256 | $147.43 | $1.2M | 5,416,000 |
| 2023-02-23 | Bancel Stephane Chief Executive Officer | Sale | −3,754 | $148.27 | $557K | 5,412,246 |
| 2023-02-23 | Bancel Stephane Chief Executive Officer | Sale | −300 | $149.86 | $45K | 5,411,946 |
| 2023-02-23 | Bancel Stephane Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −40,000 | 1,387,155 |
Page 55 of 66 · 1,314 trades